Poseida Therapeutics (PSTX) Financials

$9.50

$0.00 (0.00%)

As on 08-Jan-2025 09:30EDT

Market cap

$926 Mln

Revenue (TTM)

$151 Mln

P/E Ratio

--

P/B Ratio

10.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	150.86	64.70	130.36	0.03	--	--
Cost of Revenue	6.91	156.77	5.17	4.55	2.59	1.19
Gross Profit	143.95	-92.07	125.19	-4.52	-2.59	-1.19
Operating Expenses	210.63	194.21	190.44	0.17	0.13	78.85
Operating Profit (EBIT)	-62.50	-129.50	-59.95	-0.14	-0.13	-85.53
Other Income	--	--	2.86	19.80	0.28	--
Profit before Tax	-60.72	-123.32	-63.46	-0.12	-0.13	-86.53
Provision for Tax	-4.66	0.11	0.54	-4.53	-2.58	6.11
Profit after Tax (Net Income)	-59.40	-123.43	-64.00	4.40	2.45	-92.64
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	-64.00	-124.97	-129.78	-86.53

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	87.21	103.70	187.60	156.21	261.97	-149.51
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	128.10	98.87	110.36	69.76	79.49	274.65
Current Liabilities	78.27	71.32	53.89	43.34	30.03	21.86
Total Liabilities	371.85	273.89	351.84	269.31	371.48	147.00

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	42.87	47.41	53.27	55.44	57.49	19.82
Current Assets	250.70	226.48	298.56	213.87	314.00	127.18
Total Assets	371.85	273.89	351.84	269.31	371.48	147.00
Total Debt*	82.73	85.42	88.75	61.20	59.32	29.14
Net Current Assets	172.44	155.16	244.68	170.54	283.97	105.32

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-92.17	-26.77	-102.54	-113.33	-64.39
Cash Flow from Investing Activities	--	--	-203.33	222.38	-204.43	-42.46
Cash from Financing Activities	--	16.13	105.16	2.52	313.94	164.37
Net Cash Inflow / Outflow	--	--	-124.95	122.36	-3.82	--

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	-0.64	-1.37	-0.74	0.07	0.04	-2.33
Cash EPS ($)	--	-1.31	-0.68	0.14	0.08	-2.30
Adjusted Book Value ($)	--	1.15	2.18	2.48	4.24	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.02	-0.31	-1.63	-1.83	-1.62
Free Cash Flow per Share ($)	--	-1.06	-0.36	-1.67	-2.11	-1.75

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-53.03	-25.92	1.64	2.44	104.09
ROE (%)	-69.15	-84.75	-37.23	2.11	4.36	81.90
ROA (%)	-15.82	-39.45	-20.61	1.37	0.95	-96.44
EBIT Margin (%)	-34.23	-177.20	-45.98	-389,320.70	--	--
Net Margin (%)	-39.37	-190.76	-48.04	22.21	875.87	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	203.97	-0.50	4,172.17	--	--	--
EBIT Growth (%)	61.95	-91.26	50.71	17.87	-73.11	-106.71
Net Profit Growth (%)	55.26	-92.85	-1,553.31	79.57	102.65	-108.63
EPS Growth (%)	58.02	-0.84	-11.65	0.76	1.02	--
Book Value Growth (%)	-34.01	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	-2.46	-7.12	97.39	276.55	--
Price / Book Value	10.62	2.92	2.43	2.75	2.59	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.24	-1.62	-4.78	-2.42	-2.94	--
Close Price ($)	2.86	3.36	5.30	6.81	10.97	--
High Price ($)	4.27	8.82	7.20	13.64	17.62	--
Low Price ($)	1.83	1.54	1.82	6.15	7.63	--
Market Cap ($ Cr)	925.93	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	0.68	0.82	0.47	0.39	0.23	-0.19
Short term debt to equity ratio	0.07	0.06	0.06	0.08	0.04	-0.02
Current Ratio	3.20	3.18	5.54	4.94	10.46	5.82
Quick Ratio	3.20	3.18	5.46	--	--	--
Interest Coverage	-5.69	-13.22	-9.41	-36,216.80	-42,233.03	-24.07

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	9.78	13.93	6.97	--	--	--
Asset Turnover	0.40	0.21	0.42	0.00	--	--
Receivable days	--	51.08	12.73	--	--	--
Inventory Days	--	5.20	315.25	--	--	--
Payable days	--	6.40	395.09	390.12	401.97	1,191.73
Cash Conversion Cycle	--	49.88	-67.11	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.